AgelessRx Broadens GLP-1 Weight Care Options to Advance Longevity-First Healthcare

ANN ARBOR, Mich.–(BUSINESS WIRE)–AgelessRx, a pioneer in longevity and telehealth solutions, is expanding its suite of GLP-1 offerings to better serve customers seeking sustainable, medically guided solutions. The updated offering includes access to Zepbound® via LillyDirect® and the introduction of Compounded Liraglutide + B12. This expansion reflects AgelessRx’s mission to make science-backed, personalized longevity care […]

Novo Nordisk Partners with Telehealth for Wegovy Promotion

May 23, 2025Stat + by Katie Palmer https://ro.co/ https://lifemd.com/ Stat + reports on the evolving landscape of GLP-1 drug marketing, noting a shift in the relationship between major pharmaceutical companies like Novo Nordisk and telehealth providers. After previously battling telehealth companies offering compounded versions of their drugs, Novo Nordisk is now collaborating with specific telehealth platforms, including Ro and LifeMD. This partnership […]

Massive Study Of 215,000+ Ozempic Users Reveal Incredible Benefits Beyond Weight Loss

Shutterstock Few drugs in history have gone from initial approval to being a household name faster than the various GLP-1 drugs, including Ozempic and Wegovy. Maybe this isn’t surprising because they are known to be very effective for something that millions of people struggle with everyday. Weight loss. Many people who are on Ozempic or […]

Is Ozempic ruining your teeth? What to know about impact on dental health

Despite their widely touted benefits — primarily weight loss and diabetes control, among others — GLP-1 medications have also been linked to some unwelcome side effects. In addition to the main complaints of gastrointestinal issues, some lesser-known side effects have emerged, including mood changes, hair loss and “Ozempic face.” Now, there are rumblings on social […]

ASCO: GLP-1 receptor agonists may reduce risk for obesity-related cancer, all-cause death

For adults with diabetes and obesity, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with a reduced risk for obesity-related cancer compared with dipeptidyl peptidase-4 (DPP-4) inhibitors, according to a study scheduled to be presented at the annual meeting of the American Society of Clinical Oncology, held from May 31 to June 4 in Chicago.